GSK Acquires RAPT Therapeutics for $2.2 Billion, Allergy Drug Could Transform Treatment

RAPT Therapeutics Inc's shares surged 63.82% in pre-market trading, reaching a 52-week high of $57.40 following GSK's announcement of its acquisition for $2.2 billion.

The acquisition agreement includes a cash price of $58.00 per share, representing a 65.2% premium over the previous closing price. This strategic move enhances GSK's portfolio in respiratory and immunology treatments, particularly with the inclusion of ozureprubart, a long-acting anti-IgE monoclonal antibody currently in Phase IIb trials, which could significantly improve treatment options for food allergies.

This acquisition not only boosts RAPT's shareholder value but also positions GSK to capture a larger share of the allergy treatment market, potentially benefiting millions of patients with food allergies in the U.S.